Medicinal applications of perfluoroalkylated chain-containing compounds

Future Medicinal Chemistry

Volumn 6, Issue 10, 2014, Pages 1201-1229

  Prchalová, Eva ^a   Štěpánek, Ondřej ^a   Smrček, Stanislav ^a   Kotora, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ANALGESIC AGENT; ANDROGEN RECEPTOR ANTAGONIST; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CATHEPSIN K INHIBITOR; CHOLESTEROL ESTERASE; CYCLIN DEPENDENT KINASE INHIBITOR; DIHYDROFOLATE REDUCTASE INHIBITOR; ELASTASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ESTERASE INHIBITOR; FLUORINE DERIVATIVE; GAMMA SECRETASE INHIBITOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOSIDASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROLASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OXIDOREDUCTASE INHIBITOR; PROSTAGLANDIN INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; UNINDEXED DRUG; VITRONECTIN RECEPTOR; FLUOROCARBON;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; BACILLUS SUBTILIS; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BURNING SENSATION; CARDIOVASCULAR DISEASE; CHOLESTEROL INTAKE; DRUG DESIGN; DRUG PENETRATION; ENZYME RELEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HELICOBACTER PYLORI; HISTAMINE RELEASE; HUMAN; IC 50; LIPOPHILICITY; MALIGNANT TRANSFORMATION; MEDICINAL CHEMISTRY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHIC PAIN; OPEN ANGLE GLAUCOMA; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; REVIEW; RIGIDITY; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; TOOTH FLORA; XENOBIOTIC METABOLISM; ALKYLATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; PROCEDURES;

ALKYLATION; ANIMALS; DRUG DISCOVERY; FLUOROCARBONS; HUMANS;

EID: 84905510600     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.53     Document Type: Review

References (235)

1. Maienfisch P, Hall RG. The importance of fluorine in the life science industry. Chimia 593-598 (2004
2. Kukhar VP, Soloshonok VA. Aliphatic fluporine-containing amino acids. Russ. Chem. Rev. 60, 850-864 (1991
3. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical approach. Adv. Drug Del. Rev. 47, 209-228 (2001
4. Böhm H-J, Banner D, Bendels S et al. Fluorine in medicinal chemistry. ChemBioChem 5, 637-643 (2004
5. Bégué J-P, Bonnet-Delpon D. Recent advances (1995-2005) in fluorinated pharmaceuticals based on natural products. J. Fluorine Chem. 127, 992-1012 (2006
6. Kirk KL. Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules. J. Fluorine Chem. 127, 1013-1029 (2006
7. Isanbor C, O'Hagan D. Fluorine in medicinal chemistry: A review of anti-cancer agents. J. Fluorine Chem. 127, 303-319 (2006
8. Purser S, Moore PR, Swallow S, Gouverneur V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 37, 320-330 (2008
9. Berkowitz DB, Karukurichi KR, de la Salud-Bea R, Nelson DL, McCune CD. Use of fluorinated functionality in enzyme inhibitor development: Mechanistic and analytical advantages. J. Fluorine Chem. 129, 731-742 (2008
10. Liu P, Sharon A, Chu CK. Fluorinated nucleosides: Synthesis and biological evaluation. J. Fluorine Chem. 129, 743-766 (2008
11. Banks RE, Tatlow JC. Organofluorine Chemistry. Principles and Commercial Applications. Banks RE, Smart BE, Tatlow JC (Eds). Plenum Press, NY, USA (1994
12. Krafft MP, Riess JG. Chemistry, physical chemistry, and uses of molecular fluorocarbon-hydrocarbon diblocks, triblocks, and related compounds-unique "apolar" components for self-Assembled colloid and interface engineering. Chem. Rev. 109(5), 1714-1792 (2009
13. Riess JG. Highly fluorinated amphiphilic molecules and self-Assemblies with biomedical potential. Curr. Opin. Colloid Interf. Sci. 14, 294-304 (2009
14. Song E-H, Pohl NL. Fluorous-based small-molecule microarrays for protein, antibody and enzyme screening, Fut. Med. Chem. 1, 889-896 (2009
15. Horváth T, Curran DP, Gladysz JA. Fluorous chemistry: Scope and definition. In: The Handbook of Fluorous Chemistry. Gladysz JA, Curran DP, Horváth IT (Eds). Wiley-VCH, Weinheim, Germany, 1-4 (2004
16. Hagmann WK. Many roles for fluorine in medicinal chemistry. J. Med. Chem. 51, 4359-4369 (2008
17. Gakh AA, Burnett MN, Extreme modulation properties of aromatic fluorine. J. Fluorine Chem. 132, 88-93 (2011
18. Cametti M, Crousse B, Metrangolo P, Milani R, Resnati G. The fluorous effect in biomolecular applications. Chem. Soc. Rev. 41, 31-42 (2012
19. Rapp HM, Bacher S, Ahrens A et al. Attachment of proteins to surfaces by fluorous-fluorous interactions restoring their structure and reactivity. ChemPlusChem 77, 1066-1070 (2012
20. Krafft MP. Highly fluorinated compounds induce phase separation in, and nanostructuration of liquid media. Possible impact on, and use in chemical reactivity control. J. Polym. Sci. Part A: Polymer Chem. 44, 4251-4258 (2006
21. Hunter L. The C-F bond as a conformational tool in organic and biological chemistry. Beilstein J. Org. Chem. 6, 38 (2010
22. Kannan K. Perfluoroalkyl-And polyfluoroalkyl substances: Current and future perspectives. Environ. Chem. 8, 333-338 (2011
23. Gao J, Quiao S, Whitesides GM. Increasing binding constants to carbonic anhydrase by using 'greasy tails'. J. Med. Chem. 38, 2292-2301 (1995
24. Scozzava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic acid inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J. Med. Chem. 43, 4542-4551 (2000
25. Scozzafava A, Briganti F, Supuran CT. Carbonic acid anhydrase. Part 76. Inhibition of isozyme I, II and IV by sulfacetamide derivatives. Rev. Rom. Chim. 44, 895-906 (1999
26. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT. Carbonic acid anhydrase inhibitors. Inhibition of mitopchondrial isozyme V with aromatic and heterocyclic sulfonamides. J. Med. Chem. 47, 1272-1279 (2004
27. Blackburn GM, Türkmen H. Synthesis of α-fluoro-And α, α-difluoro-benzenemethasulfoamides: New inhibitor of carbonic acid. Org. Biomol. Chem. 3, 225-226 (2005
28. Winum J-Y, Vullo D, Casini A, Montero J-L, Scozzafa A, Supuran CT. Carbonic acid anhydrase inhibitors. Inhibition of transmembrane, tumor-Associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. 43, 5471-5477 (2003
29. Benfodda Z, Guillen F, Blancou H. Synthesis of symmetric and dissymetric bisperfluoroalkanesulfonylimides and evaluation of their inhibition on bovine carbonic anhydrase. Heteroatom Chem. 19, 542-548 (2008
30. Benfodda Z, Guillen F, Romestand B, Dahmani A, Blancou H. Synthesis and investigation of inhibition effect of fluorinated sulfonamide derivatives on carbonic anhydrase. Eur. J. Med. Chem. 45, 1225-1229 (2010
31. Krungkrai J, Krungkrai SR, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/ heterocyclic sulfoamides-in vitro and in vivo studies. Bioorg. Med. Chem. Lett. 18, 5466-5471 (2008
32. Mecinovic J, Snyder PW, Mirica KA et al. Fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the' hydrophobic wall' of carbonic anhydrase. J. Am. Chem. Soc. 133, 14017-14026 (2011
33. Scozzava A, Ilies MA, Manole G, Supuran CT. Protease inhibitors. Part 12. Synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated Nnitrobenzyl-β-Alanine hydroxamate moieties. Eur. J. Pharm. Sci. 11, 69-79 (2000
34. Scozzava A, Supuran CT. Protease inhibitors. Part 8. Synthesis of potent Clostridum histolycum collagenase inhibitors incorporating sulfonylated L-Alanine hydroxamate moieties. Bioorg. Med. Chem. 8, 637-645 (2000
35. Scozzava A, Supuran CT. Protease inhibitors: Synthesis of Clostridum histolycum collagenase inhibitors incorporating sulfonyl-l-Alanine hydroxamate moieties. Bioorg. Med. Chem. Lett. 10, 499-502 (2000
36. Supuran CT, Scozzava A. Protease inhibitors. Part 7. Inhibition of Clostridum histolycum collagenase sulfonylated L-Alanine hydroxamate moieties. Eur. J. Pharm. Sci. 10, 67-76 (2000
37. Scozzava A, Supuran CT. Protease inhibitors-Part 5. Aryl/alkylsulfonyl- And arylsulfonylureido-/arylureido lycine hydroxamate inhibitors of Clostridum histolycum collagenase. Eur. J. Med. Chem. 35, 299-307 (2000
38. Scozzava A, Supuran CT. Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties. J. Med. Chem. 43, 1858-1865 (2000
39. Supuran CT, Scozzava A. Protease inhibitors: Synthesis and QSAR study of novel classes of nonbasic trombin inhibitors incorporating sulfoguanidine and O-methylsulfonylisourea moiety at P1. J. Med. Chem. 43, 1793-1806 (2000
40. Suto MJ, Sullivan RW, Ransome LJ. Peptide inhibitors of IKB protease: Modification of the C-Termini of 2-LLF-CHO. Bioorg. Med. Chem. Lett. 6, 2925-2930 (1996
41. Kokotos G, Hsu Y-H, Burke JE et al. Potent and selective fluoroketone inbitors of group VIA calcium-independent phospholipase A2. J. Med. Chem. 53, 3602-3610 (2010
42. Acevedo-Rocha CG, Reetz MT. Tuning lipase activity with perfluorocarboxylic acids as additives. Catal. Sci. Technol. 2, 1553-1555 (2012
43. Burkard N, Bender T, Westmeier J et al. New fluorous photoaffinity labels (F-PAL) and their application in V-ATPase inhibition studies. Eur. J. Org. Chem. 2010(11), 2176-2181 (2010
44. Yamada S, Goto T, Zamaguchi T, Aihara K, Kogi K, Narita S. Synthetic study of 2-[(6, 7, 8, 9-Tetrahydro-5 Hcyclohepta[ b] pyridine-9-yl)-sulfinyl]-1 H-benzimidazole analogs and their biological properties as novel proton pump inhibitors. Chem. Phar. Bull. 43, 421-431 (1995
45. David B, Schuber F, Synthesis of α-difluoro and α-difluoro-β-Trifluoroketo-derivatives as potential inhibitors for cholesterol ester hydrolase. Bioorg. Med. Chem. Lett. 6, 1673-1676 (1996
46. Williams JR, Shea TJ. The syntheses of 3-substituted perfluoroalkyl steroids. Steroids 61, 50-57 (1996
47. Charrier N, Clarke B, Cutler L et al. Second generation of BACE-1 inhibitors part 3: Towards non hydroxylamine transition state mimetics. Bioorg. Med. Chem. Lett. 19, 3674-3678 (2009
48. Peters J-U, Galley G, Jacobsen H et al. Novel orally active, dibenzazepinone-based inhibitors. Bioorg. Med. Chem. Lett. 17, 5918-5923 (2007
49. Black WC, Bayly CI, Davis DE et al. Trifluoroethylamines as amide isosteres in inhibition of cathepsin K. Bioorg. Med. Chem. Lett. 15, 4741-4744 (2005
50. Shchegel'skii VF, Sokolov VV, Shataeva GA, Fetisov VI. Synthesis and anticholinesterase activity of fluorine containing aryliminophosphonates and phosphinates. Pharm. Chem. J. 30, 690-692 (1996
51. Krutikova VV, Krutikov VI, Erkin AV. Polyfluoroalkoxy phopshonic and phosphinic acid derivatives: II. Reversible esterase inhibitors. Russ. J. Gen. Chem. 80, 434-439 (2010
52. Krutikov VI, Alenikov SF, Gorokhova IA, Zolotukhina MM. Structure-reactivity in phosphonophosphates series. Zhu. Obsh. Khim. 64, 1479-1483 (1994
53. Palanki MSS, Gayo-Fung LM, Shevlin GI et al. Structure-Activity relationship studies of ethyl 2-[(3-methyl-2, 5-dioxo(3-pyrrolinyl))amino]-4- (trifluoromethyl)pyrimidine-5-carboxylate: An inhibitor of AP-1 and NF és B mediated gene expression. Bioorg. Med. Chem. Lett. 12, 2573-2577 (2002
54. Tseng C-F, Iwakami S, Mikajiri A et al. Inhibition in vitro of prostaglandine and leukotriene biosyntheses by cinnamoyl-β-phenethylamine and N-Acyldopamine derivatives. Chem. Pharm. Bull. 43, 396-400 (1992
55. Contino-Pépin C, Parat A, Périno S et al. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorg. Med. Chem. Lett. 19, 878-881 (2009
56. Rosowsky A, Hynes JB, Queener SF. Structure-Activity and structure-selectivity studies on diaminoquinazolines and other inhibitor of Pneumocustis carinii and Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 39, 79-86 (1995
57. Llinàs-Brunet M, Bailey M, Déziel R et al. Studies on the C-Terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 2719-2724 (1998
58. Johansson A, Pliakov A, Åkerblom E et al. Acyl sulfonamides as potent protease inhibitor of the hepatitits C virus full length NS3 (protease-helicase/NTPase): A comparative study of different C-Terminals. Bioorg. Med. Chem. 11, 2551-2568 (2003
59. Sopdeoka M, Sampe R, Kojima S et al. Synthesis of a tetronic acid library focused on inhibitor of tyrosine and dualspecifity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition. J. Med. Chem. 44, 3216-3222 (2001
60. Dancer JE, Ford MJ, Hamilton K et al. Synthesis of potent inhibitor of histidinol dehydrogenase. Bioorg. Med. Chem. Lett. 17, 2131-2136 (1996
61. Krantz A, Spencer RW, Tam TF et al. Design and synthesis of 4 H-3, 1-benzoxazin-4-ones as potent alternates ubstrate inhibitor of human leukocyte elastase. J. Med. Chem. 33, 464-479 (1990
62. Janusz MJ, Durham SL, Hare CM et al. Pharmacological evaluation of selected, orally active, peptidyl inhibitors of human neutrophile elastase. J. Pharmacol. Exp. Ther. 275, 1233-1238 (1995
63. Cregge RJ, Durham SL, Farr RA et al. Inhibition of human neutrophile elastase. 4. design, synthesis, x-ray crystallographic analysis, and structure-Activity relationship for a series of P2-modified, orally activie peptidyl pentafluoroethyl ketones. J. Med. Chem. 41, 2461-2480 (1998
64. Digenis GA, Agha BJ, Tsuji K, Kato M, Shinogi M. Peptidyl carbamates incorporating amino acid isosteres as novel elastase inhibitors. J. Med. Chem. 29, 1468-1476 (1986
65. Nakayama K, Ishida Y, Ohtsuka M et al. MexAB-OprMspecific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization. Bioorg. Med. Chem. Lett. 13, 4201-4204 (2003
66. Stevenson CN, Macmanus-Spencer LA, Luckenbach T, Luthy RC, Epel D. New perspective on perfluorochemical ecotoxicology: Inhibition and induction of an efflux transporter in marine musel, Mytilus californianus. Environ. Sci. Technol. 40, 5580-5585 (2006
67. Kimura H, Yukitake H, Tajima Y et al. ITZ-1, a clientselective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation. Chem. Biol. 17, 18-27 (2010
68. Martín-Cantalejo Y, Sáez B, Monterde MI, Murillo MT, Braña MF. Synthesis and biological activity of new bispyridinium slats of 4, 4'-bispyridyl-5, 5'-erfluoroalkyl-2, 2'-bisoxazoles. Eur. J. Med. Chem. 46, 5662-5667 (2011
69. Vegas AJ, Bradner JE, Tang W et al. Fluorous-based small molecule microarrays for ther discovery of histone deacetylase inhibitors. Angew. Chem. Int. Ed. 46, 7690-7964 (2007
70. Jones P, Bottomley MJ, Carfí A et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selectvie class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 18, 3456-3461 (2008
71. Jose B, Oniki Y, Kato T, Nishino N, Sumida Y, Yoshida M. Novel histone deacetylase inhibitors: Cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg. Med. Chem. Lett. 14, 5343-5346 (2004
72. Andrzejewska M, Pagano MA, Meggio F, Brunati AM, Kazimierczuk Z. Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinases. Bioorg. Med. Chem. 11, 3997-4002 (2003
73. Gianoncelli A, Cozza G, Orzeszko A, Meggio F, Kazimierczuk Z, Pinna LA. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK. Bioorg. Med. Chem. 17, 7281-7289 (2009
74. Sielecki TM, Johnson TL, Liu J, Muckelbauer JK et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 11, 1157-1160 (2001
75. Kozikowski AP, Nowak I, Petukhov PA et al. New amidebearing benzolactam-based protein kinase C modulators induce enahanced secretation of the amyloid precursor protein metabolite sAPPα. J. Med. Chem. 46, 364-373 (2003
76. Schitter G, Steiner AJ, Pototschnig G et al. Fluorous iminoalditols: A new family of glycosidase inhibitors and phramacological chaperones. ChemBioChem 11, 2026-2033 (2010
77. Giguėre D, André S, Bonin M-A et al. Inhibitory potential of chemical substitutions at bioinspired sites of β-dgalactopyranose on neoglycoprotein/cell surface binding of two classes of medically relevant lectins. Bioorg. Med. Chem. 19, 3280-3287 (2011
78. Brown FJ, Yee YK, Cronk LA, Hebbel KC, Krell RD, Snyder DW. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure-Activity relationship of 1, 6-disubstituted indoles and indazoles. J. Med. Chem. 33, 1771-1773 (1991
79. Biju P, Taveras AG, Dwyker MP et al. Fluoroalkyl α side chain containing 3, 4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists. Bioorg. Med. Chem. Lett. 19, 1431-1433 (2009
80. Urbahns K, Härter M, Vaupel A et al. Biphenyls as potent vitronectin receptor antagonists. Part 2. Biphenylalanine ureas. Bioorg. Med. Chem. Lett. 13, 1071-1074 (2003
81. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, Redinbo MR. Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg. Med. Chem. 15, 2156-2166 (2007
82. Ng RA, Guan JG, Alford VC et al. 2-(2, 2, 2-Trifluoroethyl)-5, 6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists. Bioorg. Med. Chem. Lett. 17, 955-958 (2007
83. Michellys P-Y, Boehm M, Chen J-H et al. Design and synthesis of novel RXRT-selective modulators with improved pharmacological profile. Bioorg. Med. Chem. Lett. 13, 4071-4075 (2003
84. Tyagarajan, S, Chakravarty PK, Zhou B et al. Discovery of novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. Lett. 20, 7479-7482 (2010
85. Zhang J, Didierlaurent S, Fortin M, Lefrançois D, Uridat E, Vevert JP. Nonpeptide endothelin antagonists: From lower affinity pyrazol-5-ols to higher affinity pyrazole-5-carboxylic acids. Bioorg. Med. Chem. Lett. 10, 1351-1355 (2000
86. Nishizawa R, Nishizama T, Hisaichi K et al. Discovery of 4-[4-({(3 R)-1-butyl-3[(R)-cyclohexyl(hydroxyl)methyl]-2, 5-dioxo-1, 4, 9-Triazaspiro[5.5] undec-9-yl}methyl) phenoxy] benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist. Bioorg. Med. Chem. 19, 4028-4042 (2011
87. Carter PH, Brown GD, Friedrich Sr. et al. Capped diaminopropionamide- glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2). Bioorg. Med. Chem. Lett. 17, 5455-5461 (2007
88. Xi N, Bo Y, Doherty EM et al. Synthesis and evaluation of tiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists. Bioorg. Med. Chem. Lett. 15, 5211-5217 (2005
89. Alker D, Arrowsmith JE, Cambell SF, Cross PE. Longacting dihydropyridine antagonists. 9. Structure reactivity relationships around amplodine. Eur. J. Med. Chem. 26, 907-913 (1991
90. Clemece F, Joliveau-Maushart C, Meier J et al. Synthese et activité analgés ique hans la sés ie des triazoles-1, 2, 4. Eur. J. Med. Chem. 20, 1453-1462 (1985
91. Fujita H, Sasaki Y, Kohno H et al. Studies of an analgesic oligopeptides. VI. Further studies of synthesis and biological properties of tripeptide alkylamides, Tyr-D-Arg-Phe-X. Chem Phar. Bull. 38, 2197-2200 (1990
92. Price WA, Wong, PC, Smith RD, Wexler RR, Timmermans PB. DuP 532: A second generation of nonpeptide angiotensin II receptor antagonists. Biochem. Biophys. Res. Commun. 177, 209 (1991
93. Wong PC, Hart SD, Chiu AT et al. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. J. Pharmocol. Exp. Ther. 259, 861-870 (1991
94. Pierce, ME, Carini DJ, Huhn GF, Wells GJ, Arnett JF. Practical synthesis and regioselective alkylation of methyl 4(5)-(pentafluoroethyl)-2- propylimidazole-5(4)-carboxylate to give DuP 532, a potent angiotensin II antagonist. J. Org. Chem. 58, 4642-4645 (1993
95. Kayahara H, Ohashi A, Tadasa K, Kato S. N-protected tripeptide inhibitors of angiotensine converting enzyme. Agric. Biol. Chem. 54, 1325-1326 (1990
96. Olimpieri F, Tambaro S, Fustero S et al. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. Bioorg. Med. Chem. Lett. 19, 4715-4719 (2009
97. DeVries VG, Largis EE, Miner TG, Shepherd RG, Upeslacis J. Potetial antiatherosclerotic agents. [(Functionalized-Alkyl) amino] benzoic acid analogs of cetaben. J. Med. Chem. 26, 1411-1421 (1983
98. Greiner J, Bayer V, Pastor R, Cambon A. 3-F-Akyl-2, 4-benzothiadiazine-1, 1-dioxides-potential diuretic and antihypertensive agents. Bull. Soc. Chim. Fr. 871-875 (1986
99. Yamamoto S, Hashiguchi S, Miki S, Igata Y, Watanabe T, Shiraishi M. Synthesis and biological evaluation of novel 1, 3-benzoxazine derivatives as K+ channel openers. Chem. Pharm. Bull. 44, 734-745 (1996
100. Horino H, Mimura T, Ohta M, Kubo H, Kitagawa M. ATP-sensitive potassium channel opener: Synthesis and antihypertensive activity of 4- bicyclyloxybenzopyrans. Bioorg. Med. Chem. Lett. 7, 437-442 (1997
101. Takahashi T, Koga H, Sato H, Ishizawa T, Taka N, Imagawa J-I. Synthesis and vasorelaxant activity of 2-fluoromethylbenzopyran potassium channel openers. Bioorg. Med. Chem. 6, 323-337 (1998
102. Taka N, Koga H, Sato H, Ishizawa T, Takahashi T, Imagawa J-I. 6-substituted 2, 2-bis(trifluoromethyl)-benzopyran-4-carboxamide K+ channel openers. Bioorg. Med. Chem. 8, 1393-1405 (2000
103. Kas'yan AO, Maletina II, Yagupol'skii LM, Markov VI, Kas'yan LI. Fluorinated sulfonamides of the norbornene series. Russ. J. Org. Chem. 31, 357-364 (1995
104. Schenk HA, Lenkowski PW, Choudhury-Mukherjee I et al. Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg. Med. Chem. 12, 979-993 (2004
105. Frolovskii VA, Garibova TL, Voronina TA, Studnev Yu N, Rozantsev GG. Synthesis and anticonvulsant properties of polyfluorinated aliphatic acid amides. Pharm. Chem. J. 35, 239-242 (2001
106. Lazer, ES, Matteo MR, Possanza GJ. Benzoimidazole derivatives with atypical antiinflammatory activity. J. Med. Chem. 30(4), 726-729 (1987
107. Bailonacute;n E, Camuesco D, Nieto A et al. The intestinal antiinflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochem. Pharm. 74, 1496-1506 (2007
108. Román J, Fernández de Arriba A, Barrón S et al. UR-1505, a new salicilate, blocks T cell activation through nuclear factor of activated T cells. Mol. Pharm. 74, 269-279 (2007
109. Tsuji K, Nakamura K, Ogino T et al. Studies on antiinflammatory agents. VI. Synthesis and pharmacological properties of 2, 3-diarylthiophenes. Chem. Pharm. Bull. 46, 279-286 (1998
110. Joshi KC, Pathak VN, Carg U. Synthesis of CNS activity of some fluorine containing pyrazole [5.1-c] [1, 2, 4] triazines. J. Ind. Chem. Soc. 60, 1074-1076 (1983
111. Kees KL, Cheeseman RS, Prozialeck DH, Steiner KE. Perfluoro-N-[4-(1 H-Tetrazol-5-ylmethyl)phenyl] alkanamides. A new class of oral antidiabetic. J. Med. Chem. 32, 11-13 (1989
112. Kees KL, Smith TM, McCaled ML et al. Perfluorocarbonbased antidiabetic agents. J. Med. Chem. 35, 944-953 (1992
113. Kees KL, Caggiano TJ, Steiner K et al. Studies on new acidic azoles as glucose-lowering agents inobese, diabetic db/db mice. J. Med. Chem. 38, 617-628 (1995
114. Gould, KJ, Manners CN, Payling DW, Suschitzky JL, Wells E. Predictive structure-Activity relationship in a seies of pyranoquinoline derivatives. A new primate model for the indetification of antiallergic activity. J. Med. Chem. 31, 1445-1453 (1988
115. Fraginals R, Schaeffer, N, Stampf J-L, Benezra C. Perfluorinated analogues of poison ivy allergens. Synthesis and skin tolerogenic activity in mice. J. Med. Chem. 34, 1024-1027 (1991
116. Kojima K, Nakajima K, Kurata H, Tabata K, Utsui Y. Synthesis of a piperidinomethylthiophene derivative as H2-Antagonist with inhibitory activity against Helicobacter pylori. Bioorg. Med. Chem. Lett. 6, 1795-1798 (1996
117. Nishat N, Rahis-ud-din, Haq MM. Synthesis and characterization of new macrocycles containing pendant groups. Synth. React. Inorg. Met. Org. Chem. 34, 335-351 (2004
118. Kazimierczuk K, Andrzejewska M, Åkaustova J, Klimeš ová V. Synthesis and antimycobacterial activity of 2-substituted halogenobenzoimidazoles. Eur. J. Med. Chem. 40, 203-208 (2005
119. Gaffar A, Coleman EJ, Esposito A, Niles H, Gibbons RJ. Nonbacterial approach to reduce colonization of plaque microflora on teeth in vitro and in vivo. J. Pharm. Sci. 74, 1228-1232 (1985
120. Goldstein EJ, Citron DM, Warren Y et al. In vitro activities of iodonium salts against oral and dental anaerobes. Antimicrob. Agents Chemother. 48, 2766-2770 (2004
121. Caillier L, Taffin de Givenchy E, Levy R, Vanderberghe Y, Geribaldi S, Guittard F. Polymerizable semi-fluorinated gemini surfactants designed for antimicrobial materials. J. Coll. Interf. Sci. 332, 201-207 (2009
122. Chandrika PM, Yakaiah T, Gayatri G et al. Click chemistry: Studies on the synthesis of novel fluorous tagged triazol-4-yl substituted quinazoline derivatives and their biological evaluation-Theoretical and experimental validation. Eur. J. Med. Chem. 45, 78-84 (2010
123. Massi L, Guittard F, Levy R, Ducchini Y, Géribald S. Preparation and antimicrobial behaviour of gemini surfactants. Eur. J. Med. Chem. 38, 519-523 (2003
124. Thebault P, de Givenchi ET, Géribaldi S, Levy R, Vandenberghe Y, Guittard F. Surface and antimicrobial properties of semi-fluorinated quaternary ammonium thiol surfactants potetantially usable for self-Assembled mono layers. J. Fluorine Chem. 131, 592-596 (2010
125. Massi L, Guittard F, Levy R, Géribaldi S. Enhanced activity of fluorinated quaternary ammonium surfactants against Pseudomonas aeruginosa. Eur. J. Med. Chem. 44, 1615-1622 (2009
126. Shao H, Jiang L, Meng W-D, Qing F-L. Synthesis and antimicrobial activity of a perfluoroalkyl-containing quaternary ammonium salt. J. Fluorine Chem. 124, 89-91 (2003
127. Sun J-Y, Li J, Qiu X-L, Qing F-L. Synthesis and structure activity relationship (SAR) of novel perfluoroalkylcontaining quaternary ammonium salts. J. Fluorine Chem. 126, 1425-1431 (2005
128. Shao H, Jiang L, Meng W-D, Qing F-L. Synthesis and antimicrobial activity of a novel perfluoroalkylated quaternary ammonium silane coupling agent. J. Fluorine Chem. 125, 721-724 (2004
129. Molina l, Perani A, Infante M-R et al. Bioactive surfuctnats containing a β-lactam group: Synthesis and properties. J. Chem. Soc., Chem. Commun. 1279-1280 (1995
130. Calvani M, Critelli L, Gallo G et al. l-Carnitine esters as" soft", broad-spectrum antimicrobioal amphiphiles. J. Med. Chem. 41, 2227-2233 (1998
131. Tan H, Xiao H. Synthesis and antimicrobial characterization of novel L-lysine gemini surfuctants pended with reactive groups. Tetrahedron Lett. 49, 1759-1761 (2008
132. Kitazaki T, Tamura N, Takasaka A et al. Optically active antifungal azoles. VI. Synthesis and antifungal activity of N-[(1 R, 2 R)-2-(2, 4-difluorophenyl)-2-hydroxy-1-methyl-3-(1 H-1, 2, 4-Triazol-1-yl)propyl]-N'-(4- substituted phenyl)-3(2 H, 4 H)-1, 2, 4-Triazolones and 5(1 H, 4 H)-Tetrazolones. Chem. Pharm. Bull. 44, 314-327 (1996
133. Shenin Yu D, Belakhov VV, Araviiskii RA. Organofluorine derivatives of nystatin. Pharma. Chem. J. 32, 109-110 (1996
134. Du Q, Zhu W, Zhao Z, Qian X, Xu Y. Novel benzo-1, 2, 3-Thiadiazoles-7- carboxylate derivatives as plant activators and the development of their agricultural applications. Agric. Food Chem. 60, 346-353 (2011
135. Stephens CE, Felder TM, Sowell Sr. JW et al. Synthesis and antiviral/antitumor evaluation of 2-Amino-And 2-carboxamido-3- Arylsulfonylthiophenes and related compounds as a new class of diarylsulfones. Bioorg. Med. Chem. 9, 1123-1132 (2001
136. Cocuzza AJ, Chidester DR, Cordova BC et al. Synthesis and evaluation of efavireny (Sustiva™) analogues as HIV-1 reverse transcriptase inhibitors: Replacement of the cyclopropylacetylene side chain. Bioorg. Med. Chem. Lett. 11, 1177-1179 (2001
137. Sawada H, Sumino E, Oue M et al. Synthesis and surfactant properties of novel acrylic acid oligomers containing perfluoro-oxa-Alkylene units: An approach to anti-human immudeficiency virus type-12 agents. J. Fluorine Chem. 74, 21-26 (1995
138. Sawada H, Katayama S, Ariyoshi Y, Hayakawa Y, Tomita T, Baba M. Fluorinated functional materials possessing biological activities: Gel formation of novel fluoroalkylated end-capped 2-Acrylamido-2-methylpropanesulfonic acid polymers under non-crosslinked conditions. J. Mater. Chem. 8, 1517-1524 (1998
139. Katsuraya K, Nakashima H, Yamamoto N, Uryu T. Synthesis of sulphated oligosaccharide gylcosides having high anti-HIV activity and the relationship between activity and chemical structure. Carbohydr. Res. 315, 234-242 (1999
140. Faroux-Corlay B, Clary L, Gadras C et al. Synthesis of a single-And double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity. Carbohydr. Res. 327, 223-260 (2000
141. Faroux-Corlay B, Greiner J, Terreux R, Cabrol-Bass D, Aubertine A-M, Fantini J. Amphiphilic anionic analogues of galactosylceramide: Synthesis, anti-HIV-1 activity, and gp120 binding. J. Med. Chem. 44, 2188-2203 (2001
142. Česnek M, Hocek M, Holý A. synthesis of acyclic nucleotide analogues derived from 2-Amino-6-C-substituted purines via cross-coupling reactions of 2-Amino-9-{2-[(diisopropoxyphosphoryl)methoxy] ethyl}-6-halopurines with diverse organometallic reagents. Coll. Czech. Chem. Commun. 65, 1357-1373 (2000
143. Saloutin VI, Il'enko VI, Piterskih IA, Platonov VG, Kiseleva IV, Paskkevich KI. Activity of derivatives of polyfluoroalkylcontaining α-ketoacids toward influenza virus. Khim. Farm. Zh. 20, 847-851 (1987
144. Schwarz B, Cech D. Eine neue methode zur einfé rung von CF3-und C2F5-gruppen in pyrimidinderivative und die anti-herpes-Aktivités der verbindungen. J. Prakt. Chem. 326, 985-993 (1984
145. LaPlante SR, Cameron DR, Aubry N et al. The conformation of a peptidyl methyl ketone inhibitor bound to the human cytomegalocytovirus protease. Angew. Chem. Int. Ed. 37, 2729-2731 (1998
146. LaPlante SR, Bonneau PR, Aubry N et al. Characterization of the human cytomegalovirus protease as an inducedfit serine protease and the implications to the design of mechanism-based inhibitors. J. Am. Chem. Soc. 121, 2974-2986 (1999
147. Perni RB, Pitlik J, Britt PD et al. Inhibitor of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. Bioorg. Med. Chem. Lett. 14, 1441-1446 (2004
148. Kobylinskaya VI, Dashevskaya TA, Shalami AS, Suleimanov SP, Kharchuk AN, Protopopova GV. Synthesis and biological activity of-5-fluoroalkylthio-6- Azauridines. Khim. Farm. Zh. 21, 290-392 (1987
149. Ekoue-Kovi K, Yearick K, Iwaniuk DP et al. Synthesis and antimalarial activity of new 4-Amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas. Bioorg. Med. Chem. 17, 270-283 (2009
150. Nga TT, Ménage C, Bégue J-P, Bonnet-Delpon D, Gantier J-C. Synthesis and antimalarial activities of fluoroalkyl derivatives of dihydroartemisin. J. Med. Chem. 41, 4101-4108 (1998
151. Held J, Soomro SA, Kremsner PG, Jansen FH, Mordmúller B. In vitro activity of new artemisin derivatives against Plasmodium falciparum clinical isolates from Gabon. Int. J. Antimicrob. Agents 37, 485-488 (2011
152. Ho NF, Sims SM, Vidmar TJ et al. Theoretical perspectives on anthelmintic drug discovery: Interplay of transport konetics, physicochemical properties, and in vitro activity of anthelmintic drugs. J. Pharm. Sci. 83, 1052-1059 (1994
153. Wickiser DI, Wilson SA, Snyder DE, Dahnke KR, Smith CK II, McDermott PJ. Synthesis and endectocidal activity of novel 1-(arylsulfonyl)-1- [(trifluoromethyl)sulfonyl] methane derivatives. J. Med. Chem. 41, 1092-1098 (1998
154. Andrzejewska M, Yópez-Mulia L, Cedilo-Rivera R et al. Synthesis, antiprotozoal and anti cancer activity of substituted 2-Trifluoromethyl-And 2-pentafluoroethylbenzimidazoles. Eur. J. Med. Chem. 37, 973-978 (2002
155. Vyas SM, Turónek J, Knötigová é P et al. Synthesis and biocompatibility evaluation of partially fluorinated pyridinium bromides. New J. Chem. 30, 944-951 (2006
156. Chao W-R, Yean D, Amin K, Green C, Jong L. Computeraided rational design: A novel agent (SR13668) designed to mimic the unique anticancer mechanism of dietary indole-3-carbinol to block AKT signaling. J. Med. Chem. 50, 3412-3415 (2007
157. Li H, Jin Y. Perfluoroalkylsulfonyloxyisoflavones: Synthesis and anti-proliferation of HL-60. Lett. Org. Chem. 6, 416-418 (2009
158. Kurumurthy C, Rao PS, Swamy V et al. Synthesis of novel alkyltriazole tagged pyrido[2, 3-d] pyrimidine derivatives and their anticancer activity. Eur. J. Med. Chem. 46, 3462-3468 (2011
159. Clavel CM, Zava O, Schmitt F et al. Thermoresponsive chlorambucil derivatives for tumour targeting. Angew. Chem. Int. Ed. 50, 7124-7127 (2011
160. Krištafor S, Gazivoda T, Cetina M, Makuc D, Plavec J, Raic-Malic S. Synthesis and structural characterization of the C-6 fluoroalkylated pyrimidine derivatives. J. Mol. Struct. 923, 19-23 (2009
161. Verdier-Pinard P, Lai J-Y, Yoo H-D et al. Structureactivity analysis of the interaction of curacin A, the potent kolchicine site atimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cell. Mol. Pharm. 53, 62-76 (1998
162. Israel M, Potti G. Adriamycin analogs. Preparation and biological evaluation of some N-perfluoroacyl analogs of daunorubicin, adriamycin, and N-(trifluoroacetyl) adriamycin 14-valerate and their 9, 10-Anhydro derivatives. J. Med. Chem. 25, 187-191 (1982
163. Renfrew AK, Juillerat-Jeanneret L, Dyson PJ. Adding diversity to ruthenium(II)-Arene anticancer (RAPTA) compounds via click chemistry: The influence of hydrophobic chains. J. Organomet. Chem. 696, 772-779 (2011
164. Renfrew AK, Scopelliti R, Dyson PJ. Use of perfluorinted phosphines to provide thermomorphic anticancer complexes for heat-based tumor targeting. Inorg. Chem. 49, 2239-2246 (2010
165. Leung S-K, Liu H-W, Lo K-W. Functionalization of luminiscent cyclometalated iridium(III)polypyridine complexes with fluorous moiety: Photophysics, proteinbinding, bioconjugation, and cellular uptake properties. Chem. Commun. 47, 10548-10550 (2011
166. Louie M-W, Fong TT-H, Lo KK-W. Luminescent rhenium(I) polypyridine
167. Subhas MS, Racharlawar SS, Sridhar B et al. New cyclopalladated benzothiophenes: A precursor for the Suzuki coupling of deactivated aryl chlorides. Org. Biomol. Chem. 8, 3001-3008 (2010
168. De Clerq L, Willem R, Gielen M, Atassi G. Synthesis, characterization and anti-Tumor activity of bis(polyfluoroalkyl)tin dihalides. Bull. Soc. Chim. Belg. 93, 1089-1097 (1984
169. Kemmer M, Dalil H, Bisemans M et al. Dibutyltin perfluoroalkanecarboxylates: Synthesis, NMR characterization and in vitro antitumor activity. J. Organomet. Chem. 608, 63-70 (2000
170. Contino C, Ollier M, Maurizis JC, Lacombe, , Pucci B. Synthesis of cotelomers derived from tris(hydroxymethyl) arylamidomethane (THAM) bearing cytosine arabinoside moieties. Preliminary investigation of their biological activity. Tetrahedron Lett. 37, 9049-9052 (1996
171. Contino C, Maurizis JC, Ollier M, Rapp M, Lacombe, Pucci B. Synthesis of new cotelomers derived from tris(hydroxymethyl)aminomethane bearing arabinofuranosylcytosine side moieties. Preliminary results on their in vitro and in vivo antitumoral activities. Eur. J. Med. Chem. 33, 809-816 (1998
172. Park SM, Yang H, Park S-K, Kim HM, Kim BH. Design, synthesis and anticancer activities of novel perfluoroalkyltriazole-Appended 2'-deoxyuridines. Bioorg. Med. Chem. Lett. 20, 5831-5834 (2010
173. Jiménez JC, López-Macià é A, Gracia C et al. Structure-Activity relationship of kahalalide F synthetic analogues. J. Med. Chem. 51, 4920-4931 (2008
174. Merhi G, Coleman AW, Devissaguet J-P, Barratt GM. Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives. J. Med. Chem. 39, 4483-4488 (1996
175. Prchalové E, Votruba I, Kotora M. Sphingosine and clavaminol H derivatives bearing fluorinated chains and their cytotoxic activity. J. Fluorine Chem. 141, 49-57 (2012
176. Kubo K, Oda K, Kaneko T, Satoh H, Nohara A. Synthesis of 2-{[(4-fluoroalkoxy-2-pyridyl)methyl] sulfinyl}-1 Hbenzimidazoles as antiulcer agents. Chem. Pharm. Bull. 38, 2853-2858 (1990
177. Han X, Pin SS, Burris KD et al. Synthesis, structure-Activity relationships, and anxiolytic activity of 7-Aryl-6, 7-dihydroimidazoimidazoles corticotrophin-releasing factor 1 receptor antagonists. Bioorg. Med. Chem. Lett. 15, 3870-3873 (2005
178. Han X, Michne JA, Pin SS et al. Synthesis, structure-Activity relationship ofimidazo[1, 2a] benzimidazoles as corticotrophin-releasing factor 1 receptor antagonists. Bioorg. Med. Chem. Lett. 15, 4029-4032 (2005
179. Zuev D, Vrudhula VM, Michne JA et al. Discovery of 6-chloro-2- Trifluoromethyl-7-Aryl-7 H-imidazo[1, 2-A] imidazole-3-ylmethylamines, a novel class of corticotropinreleasing factor receptor type 1 (CRF1R) antagonists. Bioorg. Med. Chem. Lett. 20, 3669-3674 (2010
180. Vrudhula VM, Dasgupta B, Pin SS et al. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R). Bioorg. Med. Chem. Lett. 20, 1905-1909 (2010
181. Tachibana K, Imaoka I, Yoshino H et al. Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-Activity relationships. Bioorg. Med. Chem. 15, 174-185 (2007
182. Tachibana K, Imaoka I, Yoshino H et al. Discovery and structure-Activity relationship of new steroidal compounds bearing a carboxy-Terminal side chain as androgen receptor pure antagonists. Bioorg. Med. Chem. Lett. 17, 5573-5576 (2007
183. Bradbury RH, Hales NJ, Rabow AA et al. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg. Med. Chem. Lett. 21, 5442-5445 (2011
184. van Oeveren A, Pio BA, Tegley CM et al. Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones. Bioorg. Med. Chem. Lett. 17, 1523-1526 (2007
185. van Oeveren A, Motamedi M, Martinborough E et al. New selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg. Med. Chem. Lett. 17, 1527-1531 (2007
186. Edwards JP, Higuchi RI, Winn DT et al. Nonsteroidal antiandrogen receptor agonists based on 4-(trifluoromethyl)-2 H-pyrano[3, 2-g] quinolin-2-one. Bioorg. Med. Chem. Lett. 9, 1003-1008 (1999
187. Miller CP, Bhaket P, Muthukaman N et al. Synthesis of potent, subtituted carbazoles as selective androgen receptor modulators. Bioorg. Med. Chem. Lett. 20, 7516-7520 (2010
188. Zhang P, Kern JC, Terefenko EA et al. 7-Aryl 1, 5-dihydrobenzo[ e][1, 4] oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists. Bioorg. Med. Chem. 16, 6589-6600 (2008
189. Jain N, Allan G, Linton O et al. Synthesis and SAR study of novel pseudo-steroids as potent and selective progesterone receptor antagonists. Bioorg. Med. Chem. Lett. 19, 3977-3980 (2009
190. Cleve A, Klar U, Schwede W. Beneficial effect of fluorine in the anti-progestin ZK 230211. J. Fluorine Chem. 126, 217-220 (2005
191. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867-3873 (1991
192. Hoffmann J, Bohlmann R, Heinrich N et al. Characterization of new estrogen receptor destabilizing compounds: Effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J. Natl Cancer Inst. 96, 210-218 (2004
193. Van De Velde P, Nique F, Bouchoux F et al. RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Molec. Biol. 48, 187-196 (1994
194. Renoir J-M, Stella B, Ameller T, Connault E, Opolon P, Marsaud V. Improved anti-Tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J. Ster. Biochem. Mol. Model. 102, 114-127 (2006
195. Blazejewski J-C, Wilmshurst MP, Popkin MD et al. Synthesis, characterization and biological evaluation of 7α-perfluoroalkylestradiol derivatives. Bioorg. Med. Chem. 11, 335-345 (2003
196. Kanbe Y, Kim M-H, Nishimoto M et al. Newly discovered orally active pure antiestrogens. Biorg. Med. Chem. Lett. 16, 4959-4964 (2006
197. Agouridas V, Blazejewski J-C, Cleeren A, Laios I, Leclercq G, Magnier E. Fluorous tolerance of the estrogen receptor alpha as probed by 11-perfluoroalkylestradiol derivatives. Steroids 73, 320-327 (2008
198. Eignerová é B, Sedlák D, Draíský M, Bartunek P, Kotora M. Synthesis and biochemical evaluation of a series of 17α-perfluoroalkylated estradiols as selective ligands for estrogen receptor α. J. Med. Chem. 53, 6947-6953 (2010
199. Walter G, Liebl R, von Angerer E. Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg. Med. Chem. Lett. 14, 4659-4663 (2004
200. Leichtl S, von Angerer E. 2-Phenylbenzo[b] thiophene-based antiestrogens with mammary tumor inhibiting activity. Arch. Pharm. Pharm. Med. Chem. 331, 283-289 (1998
201. Golob T, Biberger C, Walter G, von Angerer E. Antiestrogenic activities of 3, 8-dihydroxy-6, 11-dihydrobenzo[a] carbazoles with sulfur-containing side chains. Arch. Pharm. Pharm. Med. Chem. 333, 305-311 (2005
202. Kanbe Y, Kim M-H, Nishimoto M et al. Discovery of thiochroman derivatives bearing a carboxy-containing sidechain as orally active pure antiestrogens. Biorg. Med. Chem. Lett. 16, 4090-4094 (2006
203. Kanbe Y, Kim M-H, Nishimoto M et al. Discovery of thiochroman and chroman as pure antiestrogens and their structure-Activity realtionship. Biorg. Med. Chem. Lett. 16, 4090-4093 (2006
204. Kohout L, Kasal A, Strnad M. Pregnane type brassinosteroids with a four-carbon ester functionality in position 20. Collect. Czech. Chem. Commun. 61, 930-940 (1996
205. Eignerová é B, Slavíková é B, Budešínský M et al. Synthesis of fluorinated brassinosteroids based on alkene cross-metathesis and preliminary biological assessment. J. Med. Chem. 52, 5753-5757 (2009
206. Huang W-H, Hu L-Q, Ge W-Z. Synthesis of cholesterol and its analogs with fluorinated side-chains. J. Fluorine Chem. 305-318 (1989
207. Sanchez V, Manfróni A, Greiner J, Riess JG. (Perfluoroalkyl)-And 1, 2-bis(perfluoroalkyl)-iodo-And bromo ethenes: Synthesis and preliminary evaluation as contrast agents for diagnosis. Bull. Soc. Chim. Fr. 131, 648-657 (1994
208. Xu Y, Zhao Y, Qian X, Qian Z, Tian W, Zhong J. Novel, unnatural benzo-1, 2, 3,-Thiadiazole-7-carboxylate elicitors of taxoid biosynthesis. J. Agric. Food Chem. 54, 8793-8798 (2006
209. Hamper BC, Leschtinsky KL, Massey SS, Bell CL, Branningan LH, Prosch SD. Synthesis and herbicidal activity of 3-Aryl-5-(haloalkyl)-4- isooxazolecarboxamides and their derivatives. J. Agric. Food Chem. 43, 219-228 (1995
210. Crouse GD, McGowan MJ, Boisvenue RJ. Polyfluoro1, 3-diketones as systematic insecticides. J. Med. Chem. 32, 2148-2151 (1989
211. Bargar TMB, Lett RM, Johnson PL et al. Toxicity of pumilioxin 251D and synthetic analogs to the cotton pest Heliothis virescens. J. Agric. Food Chem. 43, 1044-1051 (1995
212. Saleh S, Aboul-Enein HY, Parhar R, Collinson R, Al-Mohanna F. Ca2+ dependent production of reactive oxygen metabolites by human neutrophils in response to fluorinated propranolol analogues. Biochem. Pharm. 61, 517-525 (2001
213. Sirisha B, Narsaiah B, Yakaiah T, Sastry GN, Prasad MR, Rao AR. Synthesis and theoretical studies on energetics of novel N-And O-perfluoroalkyl triazole tagged thienopyrimidines-Their potential as adenosine receptor ligands. Eur. J. Med. Chem. 45, 1739-1745 (2010
214. Siddiqi SM, Ji X, Melman N et al. A survey of nonxanthine derivatives as adenosine receptor ligands. Nucleos. Nucleot. Nucl. 15, 693-717 (1996
215. Usera AR, Dolan PM, Kensler TW, Posner GH. Antiproliferative, low-calcemic, fluorinated sulfone analogs of 1α, 25-dihydroxyvitamin D3: Chemical synthesis and biological evaluation. Bioorg. Med. Chem. 15, 5509-5518 (2007
216. Sit S-Y, Xie K, Jacutin-Porte S et al. Synthesis and SAR exploration of dinapsoline analogues. Bioorg. Med. Chem. 12, 715-734 (2004
217. Roberts LR, Bradley PA, Bunnage ME et al. Acidic triazoles as soluble guanylate cyclase stimulator. Bioorg. Med. Chem. Lett. 21, 6515 (2011
218. Voronkov MG, Baryshok VP, Kuznetsova EE, Remez IM, Deev LE. Synthesis and physiological activity of 1-(2-polyfluoroalkyl-1-iodo)silatranes. Khim-Farmatsev. Zhur. 25, 44-47 (1991
219. Murata A, Tashiro H, Ogisu A, Kato F, Naito D, Iwase M. A new series of fluorine-containing derivatives of ascorbic acid with phage-inactivating activity. Agric. Biol. Chem. 51, 2847-2849 (1987
220. Isobe Y, Tobe M, Ogita H et al. Synthesis and structure-Activity relationship of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg. Med. Chem. 11, 3641-3647 (2003
221. Fujita K, Kobayashi S, Kudo I et al. Synthesis and biological activity of fluorine-modified platelet activating factors. Chem. Pharm. Bull. 35, 647-653 (1986
222. Bakhareva EV, Voronkov MG, Arbuzov PV, Mirskov RG, Rakhlin VI, Seredin SB. Synthesis and psychotropic activity of 1-(triorganosilyl)-2-(2, 2, 3, 3, 4, 4, 4-heptafluorobutyl) aziridines. Pharm. Chem. J. 29, 186-187 (1995
223. Riess JG. Oxygen carriers ("blood substitutes")-raison d'etre, chemistry, and some physiology. Chem. Rev. 101, 2797-2920 (2001
224. Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif. Cells Blood Substit. Immobil. Biotechnol. 33, 47-63 (2005
225. Schutt EG, Klein DH, Mattrey RM, Riess JG. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: The key role of perfluorochemicals. Angew. Chem. Int. Ed. 42, 3218-3235 (2003
226. Lindner JR. Microbubbles in medical imaging: Current applications and future directions. Nature Rev. Drug Disc. 3, 527-532 (2004
227. Mees G, Dierckx R, Vangestel C, Van De Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imaging 36, 1674-1686 (2009
228. Gerber F, Krafft MP, Vandamme TF, Goldmann M, Fontaine P. Fluidization of a dipalmitoyl phosphatidylcholine monolayer by fluorocarbon gases: Potential use in lung surfactant therapy. Biophys. J. 90, 3184-3192 (2006
229. Nakahara H, Krafft MP, Shibata A, Shibata O. Interaction of a partially fluorinated alcohol (F8H11OH) with biomembrane constituents in two-component monolayers. Soft Matter 7, 7325-7333 (2011
230. Shen Y, Wen J. A new route for synthesizing cholesterol analogs with fluorocarbon side chains and their liquidcrystalline aliphatic esters. J. Fluorine Chem. 113, 13-15 (2002
231. Kannan K. Perfluoroalkyl and polyfluoroalkyl substances: Current and future perspectives. Environ. Chem. 8, 333-338 (2011
232. Monde K, Miura N, Hashimoto M, Taniguchi T, Inabe T. Conformational analysis of chiral helical perfluoroalkyl chains by VCD. J. Am. Chem. Soc. 128, 6000-6001 (2006
233. de Wolf E, Spek AL, Kuipers BWM et al. Fluorous derivatives of [Rh(COD)(dppe)] BX4 (X=F, Ph): Synthesis, physical studies and application in catalytic hydrogenantion of 1-Alkenes and 4-Alkynes. Tetrahedron 58, 3911-3922 (2002
234. Čermá J, Štastná L, Sýkora J, Císařové I, Kvíčla J. Trimethylsilylcyclopentadienes with polyfluorinated ponytails and mono-And bis(5-cyclopentadienyl) titanium(IV) complexes derived from them. Organometallics 23, 2850-2854 (2004
235. Cámpora J, Matas I, Palma P et al. Highly fluorous zirconocene(IV) complexes and their catalytic applications in the polymerization of ethylene. J. Organomet. Chem. 695, 1794-1800 (2010.